Trade Lenz Therapeutics Inc - LENZ CFD
Add to favourite- Summary
- Historical Data
Spread | 0.17 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 22.97 |
Open | 22.26 |
1-Year Change | 602.21% |
Day's Range | 22.26 - 24.47 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 17, 2025 | 23.77 | 1.52 | 6.83% | 22.25 | 24.50 | 22.23 |
Apr 16, 2025 | 22.97 | 0.60 | 2.68% | 22.37 | 23.21 | 21.60 |
Apr 15, 2025 | 23.75 | 0.73 | 3.17% | 23.02 | 24.15 | 22.31 |
Apr 14, 2025 | 23.19 | 1.60 | 7.41% | 21.59 | 23.48 | 20.79 |
Apr 11, 2025 | 20.13 | 2.69 | 15.42% | 17.44 | 20.26 | 17.44 |
Apr 10, 2025 | 18.48 | -0.94 | -4.84% | 19.42 | 19.42 | 17.71 |
Apr 9, 2025 | 20.24 | 2.76 | 15.79% | 17.48 | 20.40 | 16.26 |
Apr 8, 2025 | 18.20 | -1.65 | -8.31% | 19.85 | 20.70 | 18.02 |
Apr 7, 2025 | 19.31 | -0.64 | -3.21% | 19.95 | 21.48 | 18.72 |
Apr 4, 2025 | 21.04 | -0.52 | -2.41% | 21.56 | 21.96 | 19.96 |
Apr 3, 2025 | 22.89 | -1.06 | -4.43% | 23.95 | 24.77 | 22.78 |
Apr 2, 2025 | 25.42 | 0.25 | 0.99% | 25.17 | 25.54 | 24.49 |
Apr 1, 2025 | 25.96 | 1.19 | 4.80% | 24.77 | 26.71 | 24.77 |
Mar 31, 2025 | 25.65 | 1.09 | 4.44% | 24.56 | 25.66 | 24.02 |
Mar 28, 2025 | 25.58 | -0.94 | -3.54% | 26.52 | 26.88 | 25.22 |
Mar 27, 2025 | 26.47 | 0.71 | 2.76% | 25.76 | 26.70 | 25.69 |
Mar 26, 2025 | 26.06 | -0.44 | -1.66% | 26.50 | 26.50 | 25.07 |
Mar 25, 2025 | 26.38 | 0.99 | 3.90% | 25.39 | 27.36 | 25.39 |
Mar 24, 2025 | 26.61 | -0.02 | -0.08% | 26.63 | 27.45 | 26.27 |
Mar 21, 2025 | 26.43 | 0.77 | 3.00% | 25.66 | 26.57 | 24.36 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Graphite Bio, Inc. Company profile
About Graphite Bio Inc
Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).
Industry: | Bio Therapeutic Drugs |
611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News

ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com